Biocompatible Microemulsion Modifies the Pharmacokinetic Profile and Cardiotoxicity of Doxorubicin Juliana Uruguay Correa Vidigal AssumpçãO, Michel Leandro Campos, Marco Antonio Ferraz Nogueira Filho, Kelly Chrystina Pestana, Helen Mariana Baldan, Thalita Pedroni Formariz Pilon, Anselmoc Gomes de Oliveira, Rosângela Gonçalves Peccinini Journal of Pharmaceutical Sciences Volume 102, Issue 1, Pages 289-296 (January 2013) DOI: 10.1002/jps.23368 Copyright © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association Terms and Conditions
Figure 1 Chromatograms (a) plasma zero, (b) DOX 5 μg/mL in plasma spiked with IS (DAU). Journal of Pharmaceutical Sciences 2013 102, 289-296DOI: (10.1002/jps.23368) Copyright © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association Terms and Conditions
Figure 2 Mobile phase DOX calibration curve. Journal of Pharmaceutical Sciences 2013 102, 289-296DOI: (10.1002/jps.23368) Copyright © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association Terms and Conditions
Figure 3 Plasma DOX calibration curve. Journal of Pharmaceutical Sciences 2013 102, 289-296DOI: (10.1002/jps.23368) Copyright © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association Terms and Conditions
Figure 4 Serum CKMB activity in two groups of male Wistar rats: treated with commercial DOX and DOX‐ME. *p < 0.05 (ANOVA followed by tukey test). Journal of Pharmaceutical Sciences 2013 102, 289-296DOI: (10.1002/jps.23368) Copyright © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association Terms and Conditions
Figure 5 DOX kinetic disposition. Single i.v. dose (6 mg/kg): DOX commercial and DOX‐ME administered in two male Wistar rat groups (n = 12). Journal of Pharmaceutical Sciences 2013 102, 289-296DOI: (10.1002/jps.23368) Copyright © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association Terms and Conditions